For Dr. Wolf, who grew up in New York City and attended medical school in Brooklyn, returning to New York felt like a natural move after having been away for close to 30 years. “I always felt a strong gravitational pull to come back to New York at some point,” he said, “and I needed to find a professional opportunity to align with my personal goal. This is yet another of the many reasons why coming to Weill Cornell Medicine and NewYork-Presbyterian is so exciting.”
About Dr. Myles Wolf
Dr. Wolf received his bachelor’s degree in biology from The Johns Hopkins University, his medical degree from SUNY Downstate Health Sciences University in Brooklyn and a Master of Medical Sciences degree in clinical and physiological investigation from Harvard Medical School. He completed his internal medicine residency at Massachusetts General Hospital, followed by a clinical fellowship in nephrology at Massachusetts General Hospital and Brigham and Women's Hospital and a research fellowship in nephrology at Massachusetts General Hospital.
Ad Statistics
Times Displayed: 45175
Times Visited: 1385 Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
In 2002, Dr. Wolf joined the faculty of Harvard Medical School, rising to the position of assistant professor of medicine. In 2008 he became an associate professor of medicine at the University of Miami Miller School of Medicine, assistant dean for translational and clinical research and, eventually, professor of medicine and chief of the Division of Nephrology and Hypertension. In 2013, he became a professor of medicine at Northwestern University Feinberg School of Medicine before joining the faculty at Duke University School of Medicine in 2016 as professor of medicine and chief of the Division of Nephrology.
Dr. Wolf’s research focuses on disordered mineral homeostasis across the spectrum of kidney disease. His team investigates the role of fibroblast growth factor 23 (FGF23) in normal phosphate and calcium homeostasis, its alterations in patients with chronic kidney disease, the adverse effects of excess FGF23 on cardiovascular health and the molecular mechanisms that underlie these risk relationships. He has consistently served as a principal investigator on National Institutes of Health (NIH) grants in basic and clinical research, epidemiology, and clinical trials.
A leader in his field, Dr. Wolf has delivered numerous endowed lectures at medical institutions across the country and his research has been published in top-tier journals, including the New England Journal of Medicine, JAMA, the Journal of Clinical Investigation, Circulation and Cell Metabolism. His awards and honors include the Donald W. Seldin Young Investigator Award from the American Society of Nephrology-American Heart Association Kidney Council, and election to the American Society of Clinical Investigation, the Association of American Physicians, and the American Clinical and Climatological Society.
